UBS analyst Colin Bristow downgraded Pfizer to Neutral from Buy with a price target of $47, down from $55. COVID estimates for Pfizer still need to come down and the company’s pipeline upside is minimal in the near- to mid-term, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PFE: